thus the importance of understanding the MOA this could validate a lot of the claims that were rejected. So basically MOA not required for Pharma or FDA but potentially for a patent.
Side note, they didn’t agree that Bisantrene self rescues but rather it was just heart safe to begin with. Thus more work for Dr Jensen to firm up.
Also ARA-C previously released so prior art unless something more novel is identified. And more proof to expand to all anthracyclines and herceptin per the triangle report.
General Comments / Chat, page-7706
-
- There are more pages in this discussion • 3,432 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.88 |
Change
0.025(1.35%) |
Mkt cap ! $319.4M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.89 | $1.85 | $74.38K | 39.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18943 | $1.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.88 | 199 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |